- Home
- KPTI vs TLSA Comparison
KPTI vs TLSA Comparison
Compare KPTI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- TLSA
- Stock Information
- Founded
- KPTI 2008
- TLSA 2013
- Country
- KPTI United States
- TLSA United Kingdom
- Employees
- KPTI N/A
- TLSA N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- TLSA Health Care
- Exchange
- KPTI Nasdaq
- TLSA Nasdaq
- Market Cap
- KPTI 44.5M
- TLSA 187.0M
- IPO Year
- KPTI 2013
- TLSA 2000
- Fundamental
- Price
- KPTI $6.26
- TLSA $1.67
- Analyst Decision
- KPTI Buy
- TLSA
- Analyst Count
- KPTI 6
- TLSA 0
- Target Price
- KPTI $39.80
- TLSA N/A
- AVG Volume (30 Days)
- KPTI 102.1K
- TLSA 334.2K
- Earning Date
- KPTI 11-04-2025
- TLSA 05-06-2025
- Dividend Yield
- KPTI N/A
- TLSA N/A
- EPS Growth
- KPTI N/A
- TLSA N/A
- EPS
- KPTI N/A
- TLSA N/A
- Revenue
- KPTI $137,269,000.00
- TLSA N/A
- Revenue This Year
- KPTI $3.67
- TLSA N/A
- Revenue Next Year
- KPTI $9.40
- TLSA N/A
- P/E Ratio
- KPTI N/A
- TLSA N/A
- Revenue Growth
- KPTI N/A
- TLSA N/A
- 52 Week Low
- KPTI $3.51
- TLSA $0.63
- 52 Week High
- KPTI $16.95
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- KPTI 52.25
- TLSA 43.49
- Support Level
- KPTI $6.15
- TLSA $1.63
- Resistance Level
- KPTI $6.85
- TLSA $1.88
- Average True Range (ATR)
- KPTI 0.53
- TLSA 0.16
- MACD
- KPTI -0.15
- TLSA -0.01
- Stochastic Oscillator
- KPTI 22.86
- TLSA 32.65
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.